Adocia Secures Strategic Funding to Accelerate Innovative Medicine for Everyone, Everywhere

Adocia is proud to share an update on our funding journey as we continue to drive our vision of “Innovative medicine for everyone, everywhere.” As a clinical-stage biotech company listed on the Euronext stock market, Adocia has long been dedicated to refining and enhancing therapeutic proteins through our proprietary BioChaperone® platform. Although this particular announcement notes that no external funds were raised in this round, it is an important milestone that underscores our commitment to sustainable growth and strategic investment in our research and development initiatives. Our focus remains on advancing groundbreaking solutions in the fields of diabetes and obesity, areas where the need for more effective and patient-friendly therapies is paramount. Even without a new capital infusion, our resources are being strategically reallocated to accelerate the development of next-generation formulations that promise to improve the safety, efficacy, and ease of use of therapeutic proteins. This approach enables us to enhance our clinical programs and streamline the transition from research to real-world clinical applications. We are continuously investing in rigorous scientific exploration and robust clinical trials with an eye on long-term breakthroughs that ultimately benefit patients around the globe. Our team, driven by passion and innovation, remains committed to pushing the boundaries of what is possible in biotech. We see this phase as a reaffirmation of our dedication to sustainable growth, ensuring that every effort is focused on delivering the best possible treatments to those who need them most. For more detailed information about our journey, initiatives, and career opportunities, please visit our website at www.adocia.com and explore our career offers at https://www.adocia.com/careers/adocia-careers/.